GlassScriptPhysician profile
Vanessa Weir
NPI 1063159374
$4,206.47
in general payments reported to CMS, 2019-2025
25 companies · $692 in 2025
The $692 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $1,510 · 2024: $1,864 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,004.83 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.90 | 2023-2025 | |
| Janssen Biotech, INC. | $577.36 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.99 | 2023-2024 | Xifaxan, Trulance, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $246.76 | 2023-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $239.93 | 2023-2024 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $195.84 | 2023-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $187.82 | 2024 | Voquezna |
| Genzyme Corporation | $149.15 | 2023 | |
| Ardelyx, INC. | $133.83 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $125.48 | 2024 | Rezdiffra |
| Gilead Sciences, INC. | $114.73 | 2023 | Epclusa |
| Celgene Corporation | $114.11 | 2023-2024 | Zeposia |
| Incyte Corporation | $99.06 | 2022 | |
| Pfizer INC. | $91.11 | 2023-2024 | |
| Amgen INC. | $87.86 | 2025 | Uplizna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.62 | 2023-2024 | Entyvio, Gattex |
| Ipsen Biopharmaceuticals, INC | $41.52 | 2024 | Iqirvo |
| Axonics, INC. | $41.48 | 2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $31.79 | 2024 | |
| Braintree Laboratories, INC. | $30.74 | 2023-2024 | Sutab, Suflave |
| Lilly USA, LLC | $28.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.83 | 2024 | Dupixent |
| Exact Sciences Corporation | $17.60 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.37 | 2024 | Dificid |
| Galderma Laboratories, L.P. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.